Teriflunomide
- TRADE NAME: Aubagio (Sanofi-Aventis)
- INDICATIONS: Relapsing forms of multiple sclerosis
- CLASS: Pyrimidine synthesis inhibitor
- HALF-LIFE: N/A
FDA APPROVAL DATE: 09/12/2012
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alosetron, Caffeine, Duloxetine, Ethinylestradiol, Leflunomide, Live vaccines, Oral Contraceptives, Paclitaxel, Pioglitazone, Repaglinide, Rosiglitazone, Theophylline, Tizanidine, Warfarin
PREGNANCY CATEGORY: X
HEPATOTOXICITY and RISK OF TERATOGENICITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of teriflunomide in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 10/05/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
